Read thread👇 for key points from the #EvidencetoImpact 'Blood donor selection at the Belgian Red Cross: From evidence into policy' as we celebrate #WorldEBHCDay today! @IFRC_Europe
Patients in need of blood products are entitled to an adequate supply of safe blood. Belgian Red Cross uses a blood donor eligibility questionnaire, asking for the donor’s health and possible risk behaviour, in order to guarantee safety of both the donor and recipient.
Blood donor selection via the blood donor eligibility questionnaire remains an important part in the safety of blood supply globally.
Donor deferral criteria are historically developed based on the precautionary principle protecting safety and quality, and on supply and expense considerations.
The Centre for Evidence-Based Practice (CEBaP) decided to scientifically underpin the most common donor deferral criteria by conducting systematic reviews in order to search, analyse and critically appraise the best available evidence.
From 2009-2020 CEBaP completed 10 systematic reviews, which included 4 reviews related to donor safety. One of the reviews focused on #haemochromatosis, a hereditary disorder of iron metabolism.
CEBaP’s systematic review found no evidence that the blood of patients with haemochromatosis does not comply with the physiological quality requirements for transfusion, nor that their blood would present a greater risk to recipient safety than blood from donors without it.
The results were presented to the Belgian Senate & resulted in an amendment that was approved by the Belgian Senate and Parliament in January 2016.
In this amendment, the phlebotomies by patients with haemochromatosis can be used as regular blood donations in the case of normalisation of their ferritin status and in the absence of organ damage. This amendment was successfully implemented by BRC in May 2018.
From evidence to impact: Post-exposure prophylaxis with single-dose rifampicin. Read thread 👇 for key points from the #EvidencetoImpact story in celebration of #WorldEBHCDay!
#Leprosy is a neglected tropical disease present in more than 120 countries, with a greater burden in India and Brazil. Currently, there are over 200,000 cases registered worldwide.
In 2014, the team’s proposal for a systematic review on single-dose rifampicin (SDR) as a post-exposure prophylaxis (PEP) strategy for leprosy contacts received financial support from the Brazilian Ministry of Health.
Abuse and disrespect in childbirth care has been deemed a public health issue in Brazil, with many studies documenting the prevalence of discriminatory and hostile attitudes in childbirth care, both in the public and the private sectors.
Only 5.6% of Brazilian women have normal births without inappropriate & invasive (often not informed or consented to) interventions during vaginal birth, eg the unregulated use of oxytocin to induce or augment labour, Kristeller manoeuvre, forceps & episiotomy.
Cochrane First Aid repackages Cochrane evidence into easy-to-use formats such as blogshots (a simple one-page summary) and disseminating them via social media.
This is because 'Health information should not be restricted to healthcare professionals, but needs to be accessible and comprehensible in languages that people understand' - Cochrane Translator.
Read thread👇for key points from an #EvidencetoImpact story from Tabriz for #WorldEBHCDay, ‘Promoting informed consent in a children’s hospital’
Informed consent is considered a continuous & dynamic process, and it becomes complex in paediatric clinical practice, where parents must make decisions for their children.
The aim of the evidence implementation project was to evaluate current practice and implement best practice related to promoting informed consent in nursing and medical procedures, as well as surgical consent in the paediatric hospital.
In 2016 the Cochrane Tobacco Addiction Group (TAG) began an in-depth prioritisation project based on the @JamesLindAlliance framework to ensure that its efforts are aligned with stakeholder information needs.
TAG wanted to ensure that the voices of researchers, commissioners, funders and policymakers were heard, as well as those of healthcare providers and users.